Seminars in Nuclear Medicine
Volume 35, Issue 4 , Pages 257-265 , October 2005

Changing Concepts in the Management of Differentiated Thyroid Cancer

  • Charles M. Intenzo, MD

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Thomas Jefferson University, Philadelphia, PA.
    • Corresponding Author InformationAddress reprint requests to Charles M. Intenzo, MD, Division of Nuclear Medicine, Department of Radiology, Thomas Jefferson University, 132 S. 10th Street, Room 861, Philadelphia, PA 19107.
    • ,
  • Serge Jabbour, MD

      Affiliations

    • Division of Endocrinology and Metabolism, Department of Medicine, Thomas Jefferson University, Philadelphia, PA.
    • ,
  • Hung Q. Dam, MD

      Affiliations

    • Division of Nuclear Medicine, Department of Medicine, Christiana Hospital, Wilmington, DE.
    • ,
  • David M. Capuzzi, MD, PhD

      Affiliations

    • Division of Endocrinology and Metabolism, Department of Medicine, Thomas Jefferson University, Philadelphia, PA.

References 

  1. Schlumberger MJ . Papillary and follicular thyroid carcinoma . N Engl J Med . 1998;338:297–306
  2. Soh EY , Clark OH . Surgical considerations and approach to thyroid cancer . Endocrinol Metab Clin North Am . 1996;25:115–139
  3. Mazzaferri El , Jhiang SM . Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer . Am J Med . 1994;97:418–428
  4. Samaan NA , Schultz PN , Hickey RC , et al.   The results of various modalities of treatment of well differentiated thyroid carcinoma (A retrospective review of 1,599 patients) . J Clin Endocrinol Metab . 1992;75:714–720
  5. DeGroot LJ , Kaplan EL , McCormick M , et al.   Natural history, treatment, and course of papillary thyroid carcinoma . J Clin Endocrinol Metab . 1990;7:414–424
  6. Sawka AM , Thephamongkhol k , Brouwers M , et al.   Clinical review 170 (A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer) . J Clin Endocrinol Metab . 2004;89:3668–3676
  7. Wong JB , Kaplan MM , Myer KB , et al.   Ablative radioactive iodine therapy for apparently localized thyroid carcinoma (A decision analytic perspective) . Endocrinol Metab Clin North Am . 1990;19:741–760
  8. Hay ID , McConahey WM , Goellner JR . Managing patients with papillary thyroid carcinoma (Insights gained from the Mayo Clinic’s experience of treating 2,512 consecutive patients during 1940 through 2000) . Trans Am Clin Climatol Assoc . 2002;113:241–260
  9. Robbins RJ , Schlumberger MJ . The evolving role of I-131 for the treatment of differentiated thyroid carcinoma . J Nucl Med . 2005;46:28S–37S
  10. Schneider AB , Line BR , Goldman JM , et al.   Sequential serum thyroglobulin determinations, 131I scans and 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer . J Clin Endocrinol Metab . 1981;53:1199–1206
  11. Ladenson PW . Recombinant thyrotropin vs thyroid hormone withdrawal in evaluating patients with thyroid carcinoma . Semin Nucl Med . 2000;30:98–116
  12. Ladenson PW , Braverman L , Mazzaferri E , et al.   Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma . N Engl J Med . 1997;337:888–896
  13. Haugin B , Pacini F , Reivers C , et al.   A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer . J Clin Endocrinol Metab . 1999;84:3877–3885
  14. Robbins RJ , Tuttle RM , Sharaf RN , et al.   Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma . J Clin Endocrinol Metab . 2001;86:619–625
  15. Luster M , Lippi F , Jarzab B , et al.   RhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma (A comprehensive review) . Endocrine-Related Cancer . 2005;12:49–64
  16. Ladenson P , Pacini F , Schlumberger M , et al.   Thyroid remnant ablation; a randomized comparison of thyrotropin alfa and thyroid hormone withdrawal . 2004; Presented at 2004 Annual Meeting of the Endocrine Society, New Orleans, LA, June
  17. Mariotti S , Barbesino G , Caturegli P , et al.   Assay of thyroglobulin in serum with thyroglobulin autoantibodies (An unobtainable goal?) . J Clin Endocrinol Metab . 1995;80:468–472
  18. Schaadt B , Feldt-Rasmussen U , Rasmusson B , et al.   Assessment of the influence of thyroglobulin (Tg) autoantibodies and other interfering factors on the use of serum Tg as tumor marker in differentiated thyroid carcinoma . Thyroid . 1995;5:165–170
  19. Spencer CA , Takeuchi M , Kazarosyan M , et al.   Serum thyroglobulin autoantibodies (prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma) . J Clin Endocrinol Metab . 1998;83:1121–1127
  20. Ozata M , Suzuki S , Miyamoto T , et al.   Serum thyroglobulin in the follow-up of patients treated with differentiated thyroid cancer . J Clin Endocrinol Metab . 1994;79:98–105
  21. Pacini F , Lari R , Mazzeos  , et al.   Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer . Clin Endocrinol . 1985;23:405–411
  22. Muller-Gartner HW , Schneider C . Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer . Cancer . 1988;61:976–981
  23. Mazzaferri El , Robbins RJ , Spencer CA , et al.   A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma . J Clin Endocrinol Metab . 2003;88:1433–1441
  24. Fatourechi V , Hay ID . Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases (Including comments on the role of serum thyroglobulin monitoring in tumor surveillance) . Semin Nucl Med . 2000;30:107–114
  25. Mazzaferri El , Kloos RT . Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? . J Clin Endocrinol Metab . 2002;87:1490–1498
  26. Robbins RJ , Chon JT , Flesiher M , et al.   Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcrnioma? . J Clin Endocrinol Metab . 2002;87:3242–3247
  27. Berbano R , Naddaf S , Echmendia E , et al.   Use of iodine-123 as a diagnostic tracer for neck and whole-body scanning in patients with well-differentiated thyroid cancer . Endocr Pract . 1998;4:11–16
  28. Gulzar Z , Jana S , Young I , et al.   Neck and whole-body scanning with 5 mCi dose of I-123 as diagnostic tracer in patients with well-differentiated thyroid cancer . Endocr Pract . 2001;7:244–249
  29. Alzahrani AS , Bakheet S , Mandil MA , et al.   I-123 isotope as a diagnostic agent in follow-up of patients with differentiated thyroid cancer (Comparison with post I-131 therapy whole body scanning) . J Clin Endocrinol Metab . 2001;86:5294–5300
  30. DeGeus-Oei LF , Oe HY , Hennemann G , et al.   Sensitivity of I-123 whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer . Eur J Nucl Med Mol Imaging . 2002;29:768–774
  31. Park HM . Stunned thyroid after high dose I-131 imaging . Clin Nucl Med . 1992;17:501–502
  32. McDougall IR . 74 MBq radioiodine I-131 does not prevent uptake of therapeutic doses of I-131 (i.e. it does not cause stunning) in differentiated thyroid cancer . Nucl Med Commun . 1997;18:505–512
  33. Nemec J , Svatopluk R , Zamrazil V , et al.   Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers . J Nucl Med . 1979;20:92–97
  34. Sherman SI , Tielens ET , Sostre S , et al.   Clinical utility of post-treatment radioiodine scans in the management of patients with thyroid carcinoma . J Clin Endocrinol Metab . 1994;78:629–634
  35. Spies WG , Wojtowitcz CH , Spies SM , et al.   Value of post-therapy whole-body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high dose I-131 therapy . Clin Nucl Med . 1989;14:793–800
  36. Schlumberger M , Mancusi F , Baudin E , et al.   I-131 therapy for elevated thyrglobulin levels . Thyroid . 1997;7:273–276
  37. Pineda JD , Lee T , Ain K , et al.   Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative scan . J Clin Endocrinol Metab . 1995;80:1488–1492
  38. Park HM , Park YH , Zhou XH . Detection of remnant/metastasis without stunning (An ongoing dilemma) . Thyroid . 1997;7:277–280
  39. Leger FA , Izembart M , Dagousset F , et al.   Decreased uptake of therapeutic doses of 131-iodine after 185-MBq 131-iodine diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma . Eur J Nucl Med . 1998;25:242–246
  40. Mandel SJ , Shankar LK , Benard F , et al.   Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer . Clin Nucl Med . 2001;26:6–9
  41. Sarkar SD , Kalapparambath TP , Palestro CJ . Comparison of I-123 and I-131 for whole-body imaging in thyroid cancer . J Nucl Med . 2002;43:632–634
  42. Siddiqi A , Foley RR , Britton KE , et al.   The role of I-123-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to I-131 scanning (Avoidance of negative therapeutic uptake due to stunning) . Clin Enddocrinol . 2001;55:515–521
  43. Postgard P , Himmelman J , Lindencrona U , et al.   Stunning of iodide transport by I-131 irradiation in cultured thyroid epithelial cells . J Nucl Med . 2002;43:828–834
  44. Hu YH , Wang PW , Wang St , et al.   Influence of I-131 dose on subsequent ablation in patients with differentiated thyroid carcinoma (Discrepancy between the presence of visually apparent stunning and the impairment of successful ablation) . Nucl Med Commun . 2004;25:793–797
  45. Park HM , Perkins OW , Edmundson JW , et al.   Influence of diagnostic radioiodine on the uptake of ablative dose of iodine-131 . Thyroid . 1994;4:49–54
  46. Kao CH . Stunned thyroid after a diagnostic dose of I-131 for a whole body scan . Clin Nucl Med . 1998;23:102–104
  47. Coakley AJ . Thyroid stunning . Eur J Nucl Med . 1998;25:203–204
  48. Luster M . Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH? . Eur J Nucl Med Mol Imaging . 2004;31:924–925 [Reply to letter to editor]
  49. Hilditch TE , Dempsey MF , Bolster AA , et al.   Self-stunning in thyroid ablation (Evidence from comparative studies of diagnostic I-131 and I-123) . Eur J Nucl Med . 2002;29:783–788
  50. Wu HS , Hseu HH , Lin WY , et al.   Decreased uptake after fractionated ablative doses of iodine-131 . Eur J Nucl Med Mol Imaging . 2005;32:167–173
  51. Jeevanram RK , Shah DH , Sharma SM , et al.   Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients . Nucl Med Biol . 1986;13:277–279
  52. Dorn R , Kopp J , Heidenreich P , et al.   Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer (Largest safe dose using risk-adapted approach) . J Nucl Med . 2003;44:451–456
  53. Sabri O , Zimny M , Schreckenberg M , et al.   Does thyroid stunning exist? A model with benign thyroid disease . Eur J Nucl Med . 2000;27:1591–1597
  54. Waxman A , Ramanna L , Chapman N , et al.   The significance of I-131 scan dose in patients with thyroid cancer: Determination of ablation: concise communication . J Nucl Med . 1981;22:861–865
  55. Karam M , Giannoukakis A , Feustel PJ , et al.   Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates . Nucl Med Commun . 2003;24:489–495
  56. Morris LF , Waxman AD , Braustein GD . Thyroid stunning . Thyroid . 2003;13:333–340
  57. Medvedec M . Seeking a radiobiological explanation of thyroid stunning . Eur J Nucl Med . 2001;28:393–394 [Letter to editor]
  58. Chengazi V , O’Mara RE . Thyroid stunning after I-131 diagnostic whole-body scanning . J Nucl Med . 2001;42:986–987 [Reply to letter to editor]
  59. Cholewinski SP , Yoo KS , Klieger PS , et al.   Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq I-131 . J Nucl Med . 2000;41:1198–1202
  60. Lees W , Mansberg R , Roberts J , et al.   The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq I-131 . Eur J Nucl Med . 2002;29:1421–1427
  61. Bajen MT , Mane S , Munoz A , Garcia JR . Effect of diagnostic dose of 185 MBq I-131 on post surgical thyroid remnants . J Nucl Med . 2000;41:2038–2042
  62. Muratet JP , Daver A , Minier JF , et al.   Influence of scanning dose of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma . J Nucl Med . 1998;39:1546–1550
  63. Dam HQ , Kim SK , Lin HC , et al.   I-131 therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning . Radiology . 2004;232:527–533
  64. Nakada K , Katoh S , Kaji T , et al.   Does stunning impair prognosis of differentiated thyroid cancer? . J Nucl Med . 2002;43(suppl):328P
  65. Arlan N , Ilgan S , Serdengecti M , et al.   Post-surgical ablation of thyroid remnants with high-dose I-131 in patients with differentiated thyroid carcinoma . Nucl Med Commun . 2001;22:1021–1027
  66. Lin JD , Kao PF , Chao TC . The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma . Br J Radiol . 1998;71:307–313
  67. Venkataraman GM , Yatin M , Ain KB . Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell lin, KAT-50 . Thyroid . 1998;8:63–69
  68. Joensuu H , Ahomen A . Imaging of metastases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose . J Nucl Med . 1987;28:910–914
  69. Wang W , Macapinlac H , Larson SM , et al.   [18 F)-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic I-131 whole body scans and elevated serum thyroglobulin levels . J Clin Endocrinol Metab . 1999;84:2291–2302
  70. Chin BB , Patel P , Cohade C , et al.   Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma . J Clin Endocrinol Metab . 2004;89:91–95
  71. Schlutter B , Bohuslavizki KH , Beyer W , et al.   Impact of FDG-PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin levels and negative I-131 scan . J Nucl Med . 2001;42:71–76
  72. Wang W , Larson SM , Tuttle RM , et al.   Resistance of [F-18}-flurodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine . Thyroid . 2001;11:1169–1175
  73. Clark OH , Hoelting T . Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans . Thyroid . 1994;4:501–505
  74. McDougall IR . I-131 treatment of I-131 negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma (What is being treated?) . Thyroid . 1997;7:69–72
  75. Mazzaferri EL . Treating high thyroglobulin with radioiodine (a magic bullet or a shot in the dark?) . J Clin Endocrinol Metab . 1995;80:1485–1487
  76. Pacini F , Lippi F , Formica N , et al.   Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels . J Nucl Med . 1987;28:1888–1891
  77. Schlumberger M , Mancusi F , Baudin E , et al.   I-131 therapy for elevated thyroglobulin levels . Thryoid . 1997;7:273–276
  78. US Nuclear Regulating Commission . 1997 criteria for release of individuals administered radioactive materials . Federal Register . 1997;62:4120

PII: S0001-2998(05)00030-9

doi: 10.1053/j.semnuclmed.2005.05.003

Seminars in Nuclear Medicine
Volume 35, Issue 4 , Pages 257-265 , October 2005

Article Tools

* Image Usage & Resolution